| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
|
Quarter Ended |
|
|
Nine Months Ended |
|
| |
|
March 31, |
|
|
March 31, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
185,623 |
|
|
$ |
145,509 |
|
|
$ |
512,248 |
|
|
$ |
428,021 |
|
| Diagnostics and Genomics |
|
|
58,093 |
|
|
|
49,411 |
|
|
|
160,687 |
|
|
|
135,808 |
|
| Intersegment |
|
|
(164 |
) |
|
|
(240 |
) |
|
|
(931 |
) |
|
|
(972 |
) |
| Consolidated net sales |
|
$ |
243,552 |
|
|
$ |
194,680 |
|
|
$ |
672,004 |
|
|
$ |
562,857 |
|
| Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
88,392 |
|
|
$ |
65,046 |
|
|
$ |
238,991 |
|
|
$ |
185,456 |
|
| Diagnostics and Genomics |
|
|
10,417 |
|
|
|
7,062 |
|
|
|
27,197 |
|
|
|
8,937 |
|
| Segment operating income |
|
$ |
98,809 |
|
|
$ |
72,108 |
|
|
$ |
266,188 |
|
|
$ |
194,393 |
|
| Costs recognized on sale of acquired inventory |
|
|
(68 |
) |
|
|
- |
|
|
|
(91 |
) |
|
|
- |
|
| Amortization of acquisition related intangible assets |
|
|
(15,222 |
) |
|
|
(15,459 |
) |
|
|
(45,750 |
) |
|
|
(45,467 |
) |
| Acquisition related expenses |
|
|
(1,731 |
) |
|
|
322 |
|
|
|
(6,289 |
) |
|
|
(107 |
) |
| Stock based compensation, inclusive of employer taxes |
|
|
(11,968 |
) |
|
|
(8,088 |
) |
|
|
(41,525 |
) |
|
|
(27,505 |
) |
| Restructure costs |
|
|
- |
|
|
|
- |
|
|
|
(142 |
) |
|
|
- |
|
| Corporate general, selling, and administrative expenses |
|
|
(1,194 |
) |
|
|
(1,092 |
) |
|
|
(3,677 |
) |
|
|
(3,205 |
) |
| Consolidated operating income |
|
$ |
68,626 |
|
|
$ |
47,791 |
|
|
$ |
168,714 |
|
|
$ |
118,109 |
|
|